Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPP CAR-T in ALPP-Positive Recurrent or Metastatic Solid Tumors
NCT07123493Phase 1Terminated
- Start
- Aug 2025
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ALPP CAR-T cells in solid tumor. Primary endpoints: Incidence of Adverse Events at 24 months and Incidence of Dose Limiting Toxicity at 1 month. Started Aug 2025; status: terminated.
02
Drugs
ALPP CAR-T cells
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07123493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07123493.